A 2-year, controlled, double-blind trial of Dpenicillamine and hydroxychloroquine either alone or in combination was conducted on patients with progressive rheumatoid arthritis. The group given D-penicillamine alone improved most, but a linear fall-off in efficacy occurred. Surprisingly, the group receiving combination drug therapy did not fare as well as the group receiving D-penicillamine therapy. A subset of patients receiving hydroxychloroquine therapy had prolonged benefit. Toxicity, though not uncommon, was generally not severe.Drug therapy trials in rheumatology have usually consisted of evaluation of 1 agent at a time. We wondered if 2 drugs, hydroxychloroquine and D-penicillamine, given simultaneously might prove more efficacious than either alone, with no increase in toxicity. A study was designed to test this hypothesis and to assess the effectiveness of each drug during a 2-year followup period.
-~_~_From the Mayo Clinic and Mayo Foundation, Rochester. Minnesota (Rheumatology Trcatment Unit. Paper # 1).